MA-VERACODE
22.9.2022 14:32:58 CEST | Business Wire | Press release
Veracode, a leading global provider of application security testing solutions, today revealed that the healthcare sector takes first place for the proportion of software security flaws that are fixed, at 27 percent. The sector overtook financial services as the top-performing industry, demonstrating healthcare providers have made good headway toward the goal of making their software more secure over the past year.
The data was published in the company’s annual State of Software Security (SoSS) report v12, which analyzed 20 million scans across half a million applications in the healthcare, financial, technology, manufacturing, retail, and government sectors.
Chris Eng, Chief Research Officer at Veracode, said, “Healthcare is one of the more highly regulated sectors and is considered critical infrastructure by the government, so it’s encouraging to see the sector performs comparatively well in terms of overall flaw remediation. We hope healthcare developers and IT staff see this as a welcome ray of sunshine amidst the all-too-often gloomy realm of software security. There is still work to do, so here’s to more improvements in the years to come.”
Despite taking the top spot for fix rate, 77 percent of applications in the healthcare industry contain vulnerabilities, with 21 percent of applications containing high severity vulnerabilities. The sector also has ample room for improvement in terms of the time spent to fix flaws once they’re detected, taking up to a whopping 447 days to reach the halfway point of remediation.
Healthcare Breach Costs Are the Most Expensive
With healthcare companies incurring the highest average breach costs, at a new record high of $10.1 million*, taking proactive steps to minimize the risk of a cyberattack is imperative. Since data breaches in highly regulated industries tend to be associated with larger long-term costs that accrue over the ensuing years, the industry would benefit from even greater comprehensive efforts to address security earlier in the software development lifecycle.
Of the six industries analyzed, healthcare providers rank toward the bottom for the proportion of applications with any flaws, and second to last for the percentage of high-severity flaws—defined as those that present a serious risk to the application and organization if they were to be exploited. When it comes to the types of flaws discovered from dynamic analysis of applications in the sector, compared to other industries healthcare providers perform well for authentication issues and insecure dependencies, but have a higher incidence of cryptographic and deployment configuration issues.
Eng said, “We know that no application will ever be 100 percent free of security flaws, so it’s important that businesses take all necessary steps to minimize risk as much as possible. This includes scanning at a regular, rapid pace using multiple testing types, integrating testing tools into developer environments, and providing hands-on training to help developers understand the origin of flaws and how to fix or prevent them entirely. The healthcare sector should also take extra care to prioritize critical flaws—those vulnerabilities that could have a catastrophic impact if left unaddressed for too long.”
Andrew McCall, Vice President of Engineering, Azalea Health Innovations, said, “The biggest obstacle to building security into our workflows is that developers will treat security as just a checkbox. But security is an ongoing process and has to be top of mind throughout the software development life cycle. We chose Veracode because it was the easiest and best solution when it comes to integrating into our existing processes.”
Third-party Library Security
Considering a sharp increase in regulations to secure the software supply chain over the past year, the report analyzed third-party libraries to identify how vulnerabilities discovered through software composition analysis (SCA) behave. Overall, around 30 percent of vulnerable libraries remain unresolved after two years; however, that statistic reduces to 25 percent for the healthcare sector. In fact, while the overall ratio of vulnerable libraries found by SCA trends down steadily over time, healthcare experienced a brief upward spike before driving rates down dramatically over the last year or so.
The Veracode State of Software Security v12 healthcare snapshot is available to download here and the full report is available here.
* IBM Security and The Ponemon Institute, “Cost of a Data Breach Report 2022”: https://www.ibm.com/downloads/cas/3R8N1DZJ, July 2022
About the State of Software Security Report
The Veracode State of Software Security (SoSS) v12 analyzed the full historical data from Veracode services and customers. This accounts for a total of more than half a million applications (592,720) that used all scan types, more than a million dynamic analysis scans (1,034,855), more than five million static analysis scans (5,137,882) and more than 18 million software composition analysis scans (18,473,203). All those scans produced 42 million raw static findings, 3.5 million raw dynamic findings, and six million raw SCA findings.
The data represents large and small companies, commercial software suppliers, software outsourcers, and open-source projects. In most analyses, an application was counted only once, even if it was submitted multiple times as vulnerabilities were remediated, and new versions uploaded.
About Veracode
Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com, on the Veracode blog and on Twitter.
Copyright © 2022 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005100/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
